Rebs S, Streckfuss-Bomeke K
Front Mol Med. 2024; 3:1222986.
PMID: 39086669
PMC: 11285589.
DOI: 10.3389/fmmed.2023.1222986.
Hachmann M, Gulcan G, Rajendran R, Horing M, Liebisch G, Bachhuka A
Front Mol Med. 2024; 4:1389456.
PMID: 39086433
PMC: 11285559.
DOI: 10.3389/fmmed.2024.1389456.
Chowdhury A, Boshnakovska A, Aich A, Methi A, Vergel Leon A, Silbern I
EMBO Mol Med. 2023; 15(9):e17399.
PMID: 37533404
PMC: 10493589.
DOI: 10.15252/emmm.202317399.
Huang Y, Zhou B
Biomedicines. 2023; 11(5).
PMID: 37239170
PMC: 10216385.
DOI: 10.3390/biomedicines11051500.
Lujan A, Foresti O, Sugden C, Brouwers N, Farre A, Vignoli A
Elife. 2023; 12.
PMID: 36961129
PMC: 10042531.
DOI: 10.7554/eLife.85345.
Genome Editing and Myocardial Development.
Turan S, Chaillet J, Stapleton M, Wu Y
Adv Exp Med Biol. 2022; 1396:53-73.
PMID: 36454459
DOI: 10.1007/978-981-19-5642-3_4.
Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice.
Russo S, De Rasmo D, Signorile A, Corcelli A, Lobasso S
Sci Rep. 2022; 12(1):19847.
PMID: 36400945
PMC: 9674582.
DOI: 10.1038/s41598-022-24231-4.
Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.
Hornby B, Thompson W, AlMuqbil M, Manuel R, Abbruscato A, Carr J
Orphanet J Rare Dis. 2022; 17(1):336.
PMID: 36056411
PMC: 9438322.
DOI: 10.1186/s13023-022-02469-5.
N-oleoylethanolamide treatment of lymphoblasts deficient in Tafazzin improves cell growth and mitochondrial morphology and dynamics.
Chan J, Fernandes M, Steckel K, Bradley R, Hashemi A, Groh M
Sci Rep. 2022; 12(1):9466.
PMID: 35676289
PMC: 9178007.
DOI: 10.1038/s41598-022-13463-z.
Barth Syndrome Cardiomyopathy: An Update.
Pang J, Bao Y, Mitchell-Silbaugh K, Veevers J, Fang X
Genes (Basel). 2022; 13(4).
PMID: 35456462
PMC: 9030331.
DOI: 10.3390/genes13040656.
Mitochondrial Protein Homeostasis and Cardiomyopathy.
Wachoski-Dark E, Zhao T, Khan A, Shutt T, Greenway S
Int J Mol Sci. 2022; 23(6).
PMID: 35328774
PMC: 8953902.
DOI: 10.3390/ijms23063353.
Extended recovery of cardiac function after severe infantile cardiomyopathy presentation of Barth syndrome.
Yester J, Feingold B
JIMD Rep. 2022; 63(2):114-122.
PMID: 35281665
PMC: 8898717.
DOI: 10.1002/jmd2.12264.
Cardiomyopathies in Children and Systemic Disorders When Is It Useful to Look beyond the Heart?.
Lodato V, Parlapiano G, Cali F, Silvetti M, Adorisio R, Armando M
J Cardiovasc Dev Dis. 2022; 9(2).
PMID: 35200700
PMC: 8877723.
DOI: 10.3390/jcdd9020047.
Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid.
Sabbah H
Heart Fail Rev. 2021; 27(5):1911-1923.
PMID: 34623544
PMC: 9388406.
DOI: 10.1007/s10741-021-10177-8.
Case report of Barth syndrome: a forgotten cause of cardiomyopathy.
Rao S, Kanwal A, Padmanabhan S
Eur Heart J Case Rep. 2021; 5(7):ytab195.
PMID: 34557625
PMC: 8453413.
DOI: 10.1093/ehjcr/ytab195.
Mitochondrial nucleoid in cardiac homeostasis: bidirectional signaling of mitochondria and nucleus in cardiac diseases.
Feng Y, Huang W, Paul C, Liu X, Sadayappan S, Wang Y
Basic Res Cardiol. 2021; 116(1):49.
PMID: 34392401
PMC: 8364536.
DOI: 10.1007/s00395-021-00889-1.
The updated view on induced pluripotent stem cells for cardiovascular precision medicine.
Wang Y, Lei W, Yang J, Ni X, Ye L, Shen Z
Pflugers Arch. 2021; 473(7):1137-1149.
PMID: 33595719
DOI: 10.1007/s00424-021-02530-5.
Mitochondrial Function and Dysfunction in Dilated Cardiomyopathy.
Ramaccini D, Montoya-Uribe V, Aan F, Modesti L, Potes Y, Wieckowski M
Front Cell Dev Biol. 2021; 8:624216.
PMID: 33511136
PMC: 7835522.
DOI: 10.3389/fcell.2020.624216.
Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.
Zegallai H, Hatch G
Mol Cell Biochem. 2021; 476(3):1605-1629.
PMID: 33415565
DOI: 10.1007/s11010-020-04021-0.
Metabolic Alterations Caused by Defective Cardiolipin Remodeling in Inherited Cardiomyopathies.
Wasmus C, Dudek J
Life (Basel). 2020; 10(11).
PMID: 33187128
PMC: 7697959.
DOI: 10.3390/life10110277.